Found 6 articles
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Machavert obtains worldwide exclusive license to small molecule RAL GTPase inhibitors to treat KRAS cancers
Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)
A poster presentation reporting Natural Killer cell activation against cancer by a phospholipid molecule and its liposomal formulation MP1115
Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, was featured in an interview by CEOCFO magazine.
Machavert Pharmaceuticals announced today that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
A poster presentation reporting anti-proliferation activity for MP1000 in human KRAS mutant solid tumor models and hematological tumor models
Colorado Advanced Industries Awards Machavert $250K to Develop a Novel Therapeutics Against KRAS Cancers
-Grant award to advance RAL GTPase inhibitors in KRAS mutant solid tumors models with Machavert's drug delivery platform-